Today: 9 June 2026
Unilever PLC stock price ticks higher after Barclays lifts target — what investors watch next
23 January 2026
1 min read

Unilever PLC stock price ticks higher after Barclays lifts target — what investors watch next

London, Jan 23, 2026, 09:26 GMT — Regular session

  • Unilever shares climbed roughly 0.7% in early London trading.
  • Barclays lifted its target price, while Jefferies maintained a Sell rating.
  • Europe’s STOXX 600 fell, with investors holding back ahead of PMI releases and weighing ongoing trade tensions.

Unilever PLC shares climbed 0.7% to roughly 4,849 pence by 0926 GMT, buoyed by new broker notes that kept the spotlight on the consumer goods giant ahead of its upcoming earnings.

This move is key as investors scramble to define what “steady” means for major consumer staples amid a volatile market, where trade headlines and data risks are once again taking center stage.

This comes just before Unilever’s next earnings update, with fourth-quarter and full-year 2025 results set for Feb. 12. The company is also slated to speak at the CAGNY consumer conference on Feb. 17.

Barclays analyst Warren Ackerman stuck with a Buy rating and nudged up his target price to 5,700 pence from 5,500, a broker’s forecast for the stock over the next year, according to a dpa-AFX note on MarketScreener.

Jefferies held its ground, with analyst David Hayes sticking to a Sell rating, according to MarketScreener’s dpa-AFX feed.

European shares edged lower Friday, with the STOXX 600 shedding 0.2%, set to close the week in the red. Investors digested new friction in U.S.-Europe trade over Greenland and braced for upcoming PMI data from both regions.

Unilever’s upcoming earnings report comes on the heels of last month’s restructuring tied to the Magnum ice cream spin-off. That included an 8-for-9 share consolidation, which began trading in early December.

Some investors remain focused on the fallout from that split. On Thursday, Magnum — now overseeing Unilever’s old ice cream unit — accused former Ben & Jerry’s board chair Anuradha Mittal of “serious misconduct,” according to a court filing tied to an ongoing governance dispute at the brand, Reuters reported. Reuters

Still, the boost from broker chatter could evaporate quickly if the numbers come up short. Signs of slowing volume growth, waning pricing power, or rising costs might squeeze the trading range, especially since valuations are already stretched for defensive stocks.

Friday’s PMI numbers will give traders an immediate read on demand before attention turns to Unilever’s Feb. 12 earnings. Investors will be looking closely for clues on margins and how the newly separated business is performing as 2026 approaches.

Stock Market Today

  • Designer Brands (DBI) Beats Q1 Earnings and Revenue Estimates
    June 9, 2026, 10:04 AM EDT. Designer Brands (DBI) reported Q1 earnings of $0.07 per share, surpassing the Zacks estimate of $0.02 and reversing a year-ago loss of $0.26. Revenue hit $696.35 million, just above the $696 million consensus. The company delivered a 250% earnings surprise and has beaten EPS estimates in four consecutive quarters. Shares rose about 19.5% year-to-date, outpacing the S&P 500's 8.2% gain. Despite strong results, the stock holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. The Retail - Apparel and Shoes sector ranks among the top three industries. Future stock performance will depend on management's outlook and upcoming earnings estimate revisions, with current consensus estimates at $0.30 EPS on $744 million revenue next quarter and $0.35 EPS on $2.91 billion revenue for the fiscal year.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Experian share price rebounds after bruising slide as traders weigh Q3 update and policy risk
Previous Story

Experian share price rebounds after bruising slide as traders weigh Q3 update and policy risk

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap
Next Story

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

Go toTop